These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 11973635)
1. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635 [TBL] [Abstract][Full Text] [Related]
2. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111 [TBL] [Abstract][Full Text] [Related]
3. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide]. Zhang W; He L; Cao X Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032 [TBL] [Abstract][Full Text] [Related]
4. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547 [TBL] [Abstract][Full Text] [Related]
5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740 [TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663 [TBL] [Abstract][Full Text] [Related]
10. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632 [TBL] [Abstract][Full Text] [Related]
11. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Huang H; Li F; Gordon JR; Xiang J Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823 [TBL] [Abstract][Full Text] [Related]
13. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127 [TBL] [Abstract][Full Text] [Related]
14. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286 [TBL] [Abstract][Full Text] [Related]
15. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476 [TBL] [Abstract][Full Text] [Related]
17. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996 [TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Ju DW; Tao Q; Cheng DS; Zhang W; Zhang M; Hamada H; Cao X Gene Ther; 2000 Feb; 7(4):329-38. PubMed ID: 10694814 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Yang S; Darrow TL; Vervaert CE; Seigler HF Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]